Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition

Frank Köster, Jörg B. Engel, Andrew V Schally, Arnd Hönig, Andreas Schröer, Stephan Seitz, Florian Hohla, Olaf Ortmann, Klaus Diedrich, Stefan Buchholz

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Triple-negative breast cancers do not express receptors for estrogen or progesterone and do not overexpress HER2. These tumors have an unfavorable prognosis and at present chemotherapy is the only treatment option. Because the antagonists of growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of a variety of cancers by endocrine and paracrine/autocrine mechanisms, we evaluated the expression of GHRH receptors in human specimens of triple-negative breast cancers and the response to GHRH by in vitro models. In samples of triple-negative breast cancers we found mRNA expression for the GHRH receptor and its functional splice variant SV1 in 25 and 70% of the cases, respectively and for GHRH in 80% of the samples. Immunoreaction of SV1 was detected in the human triple-negative breast cancer cell line HCC1806 while HCC1937 was negative. The growth of HCC1806 was stimulated by GHRH(1-44)NH 2 and inhibited by GHRH antagonist MZ-J-7-118. In addition, in HCC1806 MAP-kinases ERK-1/2 were activated by GHRH. Our findings suggest the existence of an autocrine loop consisting of GHRH and GHRH receptors in triple-negative breast cancers. Our in vitro studies demonstrate that targeting the GHRH receptor may be a therapeutic option which should be evaluated in studies in vivo.

Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalBreast Cancer Research and Treatment
Volume116
Issue number2
DOIs
StatePublished - Jul 1 2009

Fingerprint

Triple Negative Breast Neoplasms
Hormone Antagonists
Growth Hormone-Releasing Hormone
Growth
Endocrine Gland Neoplasms
Progesterone Receptors
somatotropin releasing hormone receptor
Estrogen Receptors
Phosphotransferases
Drug Therapy
Cell Line
Messenger RNA
Therapeutics

Keywords

  • Breast cancer
  • GHRH antagonist
  • Growth hormone-releasing hormone
  • MAP-kinase
  • Triple-negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. / Köster, Frank; Engel, Jörg B.; Schally, Andrew V; Hönig, Arnd; Schröer, Andreas; Seitz, Stephan; Hohla, Florian; Ortmann, Olaf; Diedrich, Klaus; Buchholz, Stefan.

In: Breast Cancer Research and Treatment, Vol. 116, No. 2, 01.07.2009, p. 273-279.

Research output: Contribution to journalArticle

Köster, Frank ; Engel, Jörg B. ; Schally, Andrew V ; Hönig, Arnd ; Schröer, Andreas ; Seitz, Stephan ; Hohla, Florian ; Ortmann, Olaf ; Diedrich, Klaus ; Buchholz, Stefan. / Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. In: Breast Cancer Research and Treatment. 2009 ; Vol. 116, No. 2. pp. 273-279.
@article{44c7424211454a57857fa667b1600e2f,
title = "Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition",
abstract = "Triple-negative breast cancers do not express receptors for estrogen or progesterone and do not overexpress HER2. These tumors have an unfavorable prognosis and at present chemotherapy is the only treatment option. Because the antagonists of growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of a variety of cancers by endocrine and paracrine/autocrine mechanisms, we evaluated the expression of GHRH receptors in human specimens of triple-negative breast cancers and the response to GHRH by in vitro models. In samples of triple-negative breast cancers we found mRNA expression for the GHRH receptor and its functional splice variant SV1 in 25 and 70{\%} of the cases, respectively and for GHRH in 80{\%} of the samples. Immunoreaction of SV1 was detected in the human triple-negative breast cancer cell line HCC1806 while HCC1937 was negative. The growth of HCC1806 was stimulated by GHRH(1-44)NH 2 and inhibited by GHRH antagonist MZ-J-7-118. In addition, in HCC1806 MAP-kinases ERK-1/2 were activated by GHRH. Our findings suggest the existence of an autocrine loop consisting of GHRH and GHRH receptors in triple-negative breast cancers. Our in vitro studies demonstrate that targeting the GHRH receptor may be a therapeutic option which should be evaluated in studies in vivo.",
keywords = "Breast cancer, GHRH antagonist, Growth hormone-releasing hormone, MAP-kinase, Triple-negative",
author = "Frank K{\"o}ster and Engel, {J{\"o}rg B.} and Schally, {Andrew V} and Arnd H{\"o}nig and Andreas Schr{\"o}er and Stephan Seitz and Florian Hohla and Olaf Ortmann and Klaus Diedrich and Stefan Buchholz",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s10549-008-0120-4",
language = "English",
volume = "116",
pages = "273--279",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition

AU - Köster, Frank

AU - Engel, Jörg B.

AU - Schally, Andrew V

AU - Hönig, Arnd

AU - Schröer, Andreas

AU - Seitz, Stephan

AU - Hohla, Florian

AU - Ortmann, Olaf

AU - Diedrich, Klaus

AU - Buchholz, Stefan

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Triple-negative breast cancers do not express receptors for estrogen or progesterone and do not overexpress HER2. These tumors have an unfavorable prognosis and at present chemotherapy is the only treatment option. Because the antagonists of growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of a variety of cancers by endocrine and paracrine/autocrine mechanisms, we evaluated the expression of GHRH receptors in human specimens of triple-negative breast cancers and the response to GHRH by in vitro models. In samples of triple-negative breast cancers we found mRNA expression for the GHRH receptor and its functional splice variant SV1 in 25 and 70% of the cases, respectively and for GHRH in 80% of the samples. Immunoreaction of SV1 was detected in the human triple-negative breast cancer cell line HCC1806 while HCC1937 was negative. The growth of HCC1806 was stimulated by GHRH(1-44)NH 2 and inhibited by GHRH antagonist MZ-J-7-118. In addition, in HCC1806 MAP-kinases ERK-1/2 were activated by GHRH. Our findings suggest the existence of an autocrine loop consisting of GHRH and GHRH receptors in triple-negative breast cancers. Our in vitro studies demonstrate that targeting the GHRH receptor may be a therapeutic option which should be evaluated in studies in vivo.

AB - Triple-negative breast cancers do not express receptors for estrogen or progesterone and do not overexpress HER2. These tumors have an unfavorable prognosis and at present chemotherapy is the only treatment option. Because the antagonists of growth hormone-releasing hormone (GHRH) have been shown to inhibit growth of a variety of cancers by endocrine and paracrine/autocrine mechanisms, we evaluated the expression of GHRH receptors in human specimens of triple-negative breast cancers and the response to GHRH by in vitro models. In samples of triple-negative breast cancers we found mRNA expression for the GHRH receptor and its functional splice variant SV1 in 25 and 70% of the cases, respectively and for GHRH in 80% of the samples. Immunoreaction of SV1 was detected in the human triple-negative breast cancer cell line HCC1806 while HCC1937 was negative. The growth of HCC1806 was stimulated by GHRH(1-44)NH 2 and inhibited by GHRH antagonist MZ-J-7-118. In addition, in HCC1806 MAP-kinases ERK-1/2 were activated by GHRH. Our findings suggest the existence of an autocrine loop consisting of GHRH and GHRH receptors in triple-negative breast cancers. Our in vitro studies demonstrate that targeting the GHRH receptor may be a therapeutic option which should be evaluated in studies in vivo.

KW - Breast cancer

KW - GHRH antagonist

KW - Growth hormone-releasing hormone

KW - MAP-kinase

KW - Triple-negative

UR - http://www.scopus.com/inward/record.url?scp=67649225452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649225452&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-0120-4

DO - 10.1007/s10549-008-0120-4

M3 - Article

C2 - 18629632

AN - SCOPUS:67649225452

VL - 116

SP - 273

EP - 279

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -